课题基金 / 基金详情

抗真菌剤ボリコナゾールによる芳香族炭化水素受容体を介した皮膚癌進展機序の解明

抗真菌剤ボリコナゾールによる芳香族炭化水素受容体を介した皮膚癌進展機序の解明
阐明抗真菌剂伏立康唑引起的芳香烃受体介导的皮肤癌进展机制
批准号:
16K19714
负责人:
池谷 茂樹
金额:
$2.41万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Young Scientists (B)
财政年份:
2016
资助国家:
日本
项目状态:
已结题
起止时间:
2016-04-01 至 2017-03-31

项目摘要

项目成果

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Voriconazole (VRCZ) induces the development of UV-associated skin cancers. The mechanism underlying the VRCZ-induced carcinogenesis has been largely unknown.Clinical studies (VRCZ-induced skin tumors were clinically summarized, and VRCZ-induced actinic keratosis (AK) were histopathologically compared with ordinary AK) suggested that VRCZ can strongly evoke the tumor formation of keratinocytes (KC)s under a certain immunocompromised condition and its tumorigenesis is not simply caused by photosensitivity. In vitro, we showed that VRCZ metabolites plus UVA generated reactive oxygen species and resultant DNA damage of the epidermis, but did not induce substantial apoptosis in KCs. Furthermore, VRCZ per se stimulates aryl hydrocarbon receptor (AhR) and upregulates COX-2, which is a pivotal enzyme for the promotion of UV-associated tumors, in an AhR-ARNT dependent manner of the classical (genomic) pathway.Our findings suggest that VRCZ primarily promotes the tumor development of preexisted UV-damaged KCs in clinical settings, while the phototoxic moieties of VRCZ metabolites may participate in the initiation phase.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
抗真菌剤ボリコナゾール投与中に生じた光線角化症とその発症機序の検討
抗真菌药伏立康唑用药过程中发生的光化性角化病及其发病机制的研究
DOI: --
发表时间: 2016
期刊:
影响因子: --
作者: [Daisuke Ieda, Ikumi Hori, Yuji Nakamura, Hironori Ohshita, Yutaka Negishi Tsutomu Shinohara, Ayako Hattori, Takenori Kato, Sachiko Inukai Katsumasa Kitamura, Shinji Kunishima, Tomoki Kawai, Osamu Ohara, Shinji Saitoh, 池谷茂樹]
通讯作者: 池谷茂樹